PON1通过SR-BI减少肿瘤相关巨噬细胞募集和M2极化抑制肝癌的侵袭和转移

批准号:
81572298
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
黄成
依托单位:
学科分类:
H1818.肿瘤免疫治疗
结题年份:
2019
批准年份:
2015
项目状态:
已结题
项目参与者:
朱小东、易勇、丁光宇、沈英皓、陈军、叶伯根、马德宁、蔡浩、柴宗涛
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
PON1(对氧磷酯酶-1)是由肝脏合成的钙离子依赖性芳香酯酶,其血清浓度及活性在心血管等疾病中明显下降。申请者前期基于蛋白组学的研究发现合并血管侵犯的肝癌患者血清中及肿瘤组织中PON1的水平显著下降,PON1低表达的患者预后较差。预实验中,我们发现过表达PON1的肝癌细胞在体外的增殖及侵袭能力无明显下降,但接种于裸鼠原位后,肿瘤生长明显被抑制,提示PON1通过影响肝癌微环境间接抑制肿瘤进展。动物实验中,PON1表达可显著抑制巨噬细胞(MΦ)浸润,提示MΦ浸润和M2型极化减少可能是PON1抑制肝癌进展的机制之一。动脉粥样硬化相关研究提示PON1可能通过SR-BI(B类I型清道夫受体)表达抑制单核-MΦ分化、募集和减少泡沫细胞形成。本项目中,我们拟通过体内外实验及临床标本研究,探索SR-BI介导的MΦ募集减少和M2极化抑制是否为其中的关键机制,通过对该机制的深入研究,为肝癌转移治疗提供新思路。
英文摘要
PON1 (paraoxonase 1) belongs to a family of calcium-dependent hydrolase proteins, mainly synthesized in liver. Serum PON1 concentration and activity were inversely associated with cardiac-vascular disease. Our previous research based on proteomics found that the serum concentration of PON1 significantly decreased in the hepatocellular carcinoma (HCC) patients with vascular invasion as compared with those without vascular invasion, and the tumoral expression also decreased. Downregulation of PON1 expression in tumoral tissue was a maker of poor prognosis for the patients who underwent curtive liver resection for HCC. In vitro studies, we found that overexpression of PON1 in hepatoma cells did not suppress the proliferation and invasion of these cells, however, in vivo tumor growth was significantly restrained when these cells were implanted into the liver of nude mice. These results indicated that PON1 suppressed tumor progression as a non-cell-autonomous manner, that is, in a way by modulating the tumor microenvironment and then inhibited tumor progress indirectly but not changing the tumor cells directly. In vivo studies also revealed that PON1 significantly suppress intra-tumoral macrophage infiltration, indicating that targeting tumor-associated macrophages and inhibition of the M2 phenotype could be one of the mechanisms. In the studies of atherosclerosis, SR-BI (scavenger receptor class B type I) was believed to be the key molecule that mediated the macrophage-modulating effects of PON1, by down-regulating the expression of SR-BI, PON1 inhibited the differentiation, recruitment of macrophages and the formation of form cells, which is a tissue specific macrophages. In this project, we are aiming to verify the anti-invasive effects of PON1 in HCC, and study whether SR-BI–mediated depletion of macrophages and M2 polarization was the key mechanism. These studies could provide a novel strategy for the treatment for tumor metastasis in HCC.
PON1(对氧磷酯酶-1)是由肝脏合成的钙离子依赖性芳香酯酶,其血清浓度及活性在心血管等疾病中明显下降。前期基于蛋白组学的研究发现合并血管侵犯的肝癌患者血清中及肿瘤组织中PON1的水平显著下降,PON1低表达的患者预后较差。进一步研究发现过表达PON1的肝癌细胞在体外的增殖及侵袭能力无明显下降,但接种于裸鼠原位后,肿瘤生长明显被抑制,提示PON1通过影响肝癌微环境间接抑制肿瘤进展。动物实验中,PON1表达可显著抑制巨噬细胞(MΦ)浸润,揭示MΦ浸润和M2型极化减少是PON1抑制肝癌进展的机制。机制研究发现PON1通过SR-BI表达抑制单核-MΦ分化。申请者通过体内外实验及临床标本研究,深入解析PON1在肝癌微环境的作用,为肝癌转移治疗提供新思路。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition
硒结合蛋白1减少与肝内胆管癌的不良预后相关,并促进细胞上皮-间质转化
DOI:--
发表时间:2018
期刊:Am J Transl Res
影响因子:--
作者:Xin-Yu Zhang;Ping-Ting Gao;Xuan Yang;Jia-Bin Cai;Guang-Yu Ding;Xiao-Dong Zhu;Cheng Huang
通讯作者:Cheng Huang
NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells.
NOD样受体X1通过抑制肝细胞癌细胞上皮间质转化和诱导衰老发挥抑癌作用
DOI:10.1186/s13045-018-0573-9
发表时间:2018-02-26
期刊:Journal of hematology & oncology
影响因子:28.5
作者:Hu B;Ding GY;Fu PY;Zhu XD;Ji Y;Shi GM;Shen YH;Cai JB;Yang Z;Zhou J;Fan J;Sun HC;Kuang M;Huang C
通讯作者:Huang C
Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection
影响初次 R0 手术切除后 WHO 分类 G1 和 G2 胃肠胰神经内分泌肿瘤异时性肝转移预后的危险因素
DOI:10.1186/s12885-019-5457-z
发表时间:2019-04-08
期刊:BMC CANCER
影响因子:3.8
作者:Lv, Yang;Han, Xu;Huang, Cheng
通讯作者:Huang, Cheng
Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.
巴塞罗那临床肝癌 (BCLC) 0 期或 B 期肝细胞癌患者的微血管侵犯临床价值有限
DOI:10.1186/s12885-017-3050-x
发表时间:2017-01-17
期刊:BMC cancer
影响因子:3.8
作者:Huang C;Zhu XD;Ji Y;Ding GY;Shi GM;Shen YH;Zhou J;Fan J;Sun HC
通讯作者:Sun HC
Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4
硒结合蛋白 1 的缺失和随后 CXCR4 的上调增强了肝细胞癌的侵袭潜力
DOI:--
发表时间:2018
期刊:American Journal of Cancer Research
影响因子:5.3
作者:Gao Ping-Ting;Ding Guang-Yu;Yang Xuan;Dong Rui-Zhao;Hu Bo;Zhu Xiao-Dong;Cai Jia-Bin;Shi Guo-Ming;Shen Ying-Hao;Zhou Jian;Fan Jia;Sun Hui-Chuan;Huang Cheng;Gao Ping-Ting;Ding Guang-Yu;Yang Xuan;Dong Rui-Zhao;Hu Bo;Zhu Xiao-Dong;Cai Jia-Bin;Shi Guo-Ming;She
通讯作者:She
NLRX1缺失介导的琥珀酰化修饰失衡对肝癌免疫检查点抑制剂耐药的促进作用与机制研究
- 批准号:--
- 项目类别:面上项目
- 资助金额:55万元
- 批准年份:2020
- 负责人:黄成
- 依托单位:
PON1介导肝细胞癌外泌microRNAs调控肿瘤MDSC和TAM抑制肝癌侵袭和转移的机制研究
- 批准号:81871929
- 项目类别:面上项目
- 资助金额:55.0万元
- 批准年份:2018
- 负责人:黄成
- 依托单位:
肝细胞癌门静脉微癌栓的蛋白质分子标记研究
- 批准号:30600605
- 项目类别:青年科学基金项目
- 资助金额:23.0万元
- 批准年份:2006
- 负责人:黄成
- 依托单位:
国内基金
海外基金
